HRMY

Harmony Biosciences Holdings, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-24

Figures on this page computed 2026-11-08 12:32 UTC

Last close

34.42USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-24

12.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
53.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
18.3%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
40.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
0.19Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Follow one dollar

lens 1 of 9

After what it costs to make

77.2%

After running the business

24%

After interest and tax

18.3%

After what it must reinvest

40.1%

Kept after the dividend

n/a

after what it costs to make, 77.2% of sales; after running the business, 24.0% of sales; after interest and tax, 18.3% of sales; after what it must reinvest, 40.1% of sales

The five stops

4 of 5 read

After what it costs to make670,111,00077.2%
After running the business208,469,00024%
After interest and tax158,687,00018.3%
After what it must reinvest347,889,00040.1%
Kept after the dividendn/an/a

The last stop is empty on purpose. This filing does not tag a common dividend, so what is kept after it cannot be worked out. That is not the same fact as a company that paid no dividend, and we will not print a zero for it.

What is left after the dividend is not held for this company.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-24

Sales868,453,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
After what it costs to make670,111,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
After running the business208,469,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
After interest and tax158,687,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
After what it must reinvest347,889,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself
Kept after the dividendn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
The filing itself